steatosis; fatty liver; nonalcoholic fatty liver disease (NAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD)

From Aaushi
Jump to navigation Jump to search

Introduction

New nomenclature: NAFLD will be called

metabolic dysfunction-associated steatotic liver disease (MASLD)[34]

Diagnosis of exclusion in overweight patients with preserved liver function.

Generally a benign condition.

Etiology

Epidemiology

Pathology

Genetics

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

More general terms

More specific terms

Additional terms

References

  1. kaiser permanente nothern california, lab tips, sept. 1999
  2. journal watch vol 19 #22, pg 173, nov 15, 1999
  3. journal watch vol 19 #24, pg 190, dec 15, 1999
  4. medical knowledge self assessment program (mksap) 11, 16, 18, 19. american college of physicians, philadelphia 1998, 2012, 2018, 2021.
  5. 5.0 5.1 5.2 prescriber's letter 12(6): 2005 use of statins and thiazolidinediones in patients with nonalcoholic fatty liver disease detail-document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210620&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 6.2 ekstedt m et al, long-term follow-up of patients with nafld and elevated liver enzymes hepatology 2006, 44:865 pmid: https://www.ncbi.nlm.nih.gov/pubmed/17006923
  7. 7.0 7.1 petersen kf et al apolipoprotein c3 gene variants in nonalcoholic fatty liver disease. n engl j med 2010 mar 25; 362:1082 pmid: https://www.ncbi.nlm.nih.gov/pubmed/20335584
    riordan sm and williams r. gut flora and hepatic encephalopathy in patients with cirrhosis. n engl j med 2010 mar 25; 362:1140. pmid: https://www.ncbi.nlm.nih.gov/pubmed/20335591
  8. 8.0 8.1 foster t et al. atorvastatin and antioxidants for the treatment of nonalcoholic fattly liver disease: the st francis heart study randomized clinical trial. am j gastroenterol 2011 jan; 106:71 pmid: https://www.ncbi.nlm.nih.gov/pubmed/20842109
  9. 9.0 9.1 williams cd et al. prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. gastroenterology 2011 jan; 140:124 pmid: https://www.ncbi.nlm.nih.gov/pubmed/20858492
  10. 10.0 10.1 lazo m et al. non-alcoholic fatty liver disease and mortality among us adults: prospective cohort study. bmj 2011 nov 18; 343:d6891 pmid: https://www.ncbi.nlm.nih.gov/pubmed/22102439
  11. 11.0 11.1 11.2 11.3 11.4 11.5 chalasani n et al. the diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. hepatology 2012 jun; 55:2005 pmid: https://www.ncbi.nlm.nih.gov/pubmed/22488764 (corresponding ngc guideline withdrawn dec 2017)
  12. perlemuter g, bigorgne a, cassard-doulcier am, naveau s. nonalcoholic fatty liver disease: from pathogenesis to patient care. nat clin pract endocrinol metab. 2007 jun;3(6):458-69. pmid: https://www.ncbi.nlm.nih.gov/pubmed/17515890
  13. cheung o, sanyal aj. recent advances in nonalcoholic fatty liver disease. curr opin gastroenterol. 2010 may;26(3):202-8 pmid: https://www.ncbi.nlm.nih.gov/pubmed/20168226
  14. 14.0 14.1 14.2 14.3 14.4 14.5 anello j, feinberg b, heinegg j, lindsey r, wojdylo c, wong o. medcsape oncology. august 2014 recommendations for nonalcoholic fatty live disease from the world gastroenterology organization (wgo) http://reference.medscape.com/features/slideshow/guidelines-review/august2014
  15. chalasani n, younossi z, lavine je et al the diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american gastroenterological association, american association for the study of liver diseases, and american college of gastroenterology. gastroenterology. 2012 jun;142(7):1592-609 pmid: https://www.ncbi.nlm.nih.gov/pubmed/22656328 (corresponding ngc guideline withdrawn dec 2017)
  16. 16.0 16.1 16.2 16.3 16.4 16.5 kim d, kim wr. non-obese fatty liver disease. clin gastroenterol hepatol 2016 aug 28; pmid: https://www.ncbi.nlm.nih.gov/pubmed/27581063
  17. 17.0 17.1 17.2 vanwagner lb et al. alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease. gastroenterology 2017 aug 9 pmid: https://www.ncbi.nlm.nih.gov/pubmed/28802566
  18. 18.0 18.1 zelber-sagi s, ivancovsky-wajcman d, fliss isakov n, et al. high red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. j hepatol 2018 mar 15; pmid: https://www.ncbi.nlm.nih.gov/pubmed/29571924 https://linkinghub.elsevier.com/retrieve/pii/s0168827818300588
  19. 19.0 19.1 simon tg, henson j, osganian s et al. daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. clin gastroenterol hepatol 2019 may 8; pmid: https://www.ncbi.nlm.nih.gov/pubmed/31077838 https://www.cghjournal.org/article/s1542-3565(19)30493-8/pdf
  20. 20.0 20.1 koutoukidis da, astbury nm, tudor ke et al. association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. jama intern med 2019 jul 1; pmid: https://www.ncbi.nlm.nih.gov/pubmed/31260026 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737321
    adler e, brandman d. treatment of fatty liver disease - time to implement common sense measures. jama intern med 2019 jul 1; pmid: https://www.ncbi.nlm.nih.gov/pubmed/31260055 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737317
  21. 21.0 21.1 gawrieh s, wilson la, cummings ow, et al. histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. am j gastroenterol 2019 oct; 114:1626 pmid: https://www.ncbi.nlm.nih.gov/pubmed/31517638 https://journals.lww.com/ajg/abstract/2019/10000/histologic_findings_of_advanced_fibrosis_and.13.aspx
  22. 22.0 22.1 alexander m, loomis ak, van der lei j et al. non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million european adults. bmj 2019 oct 8; 367:l5367 pmid: https://www.ncbi.nlm.nih.gov/pubmed/31594780 free pmc article
  23. 23.0 23.1 samuel vt, shulman gi nonalcoholic fatty liver disease, insulin resistance, and ceramides. n engl j med 2019; 381:1866-1869 pmid: https://www.ncbi.nlm.nih.gov/pubmed/31693811 https://www.nejm.org/doi/full/10.1056/nejmcibr1910023
  24. 24.0 24.1 natarajan y, kramer jr, yu x et al. risk of cirrhosis and hepatocellular cancer in patients with non-alcoholic fatty liver disease and normal liver enzymes. hepatology 2020 feb 5; pmid: https://www.ncbi.nlm.nih.gov/pubmed/32022277 https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31157
  25. 25.0 25.1 nejm knowledge+ question of the week. dec 15, 2020 https://knowledgeplus.nejm.org/question-of-week/1577/
    chalasani n et al. the diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. hepatology 2018 jan; 67:328 pmid: https://www.ncbi.nlm.nih.gov/pubmed/28714183
  26. 26.0 26.1 rodriguez la, shiboski sc, bradshaw pt et al. predicting non-alcoholic fatty liver disease for adults using practical clinical measures: evidence from the multi-ethnic study of atherosclerosis. j gen intern med 2021 sep; 36:2648 pmid: https://www.ncbi.nlm.nih.gov/pubmed/33501527 https://link.springer.com/article/10.1007%2fs11606-020-06426-5
  27. 27.0 27.1 27.2 kanwal f, shubrook jh, adams la et al. clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. gastroenterology 2021 nov; 161:1657. pmid: https://www.ncbi.nlm.nih.gov/pubmed/34602251 https://www.gastrojournal.org/article/s0016-5085(21)03384-9/fulltext
  28. 28.0 28.1 aminian a, al-kurd a, wilson r et al association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. jama. published online november 11, 2021. pmid: https://www.ncbi.nlm.nih.gov/pubmed/34762106 https://jamanetwork.com/journals/jama/fullarticle/2786270
  29. 29.0 29.1 hamza z nafld tied to higher dementia risk
    findings were stronger among patients with comorbid heart disease. medpage today july 13, 2022 https://www.medpagetoday.com/neurology/dementia/99704https://www.medpagetoday.com/neurology/dementia/99704
    shang y, widman l, hagstrom h nonalcoholic fatty liver disease and risk of dementia: a population-based cohort study. neurology. 2022. july 13 pmid: https://www.ncbi.nlm.nih.gov/pubmed/35831178 https://n.neurology.org/content/early/2022/07/13/wnl.0000000000200853
  30. 30.0 30.1 crist c exercise training reduces liver fat in patients with nafld, even without weight loss. medscape. february 13, 2023
  31. 31.0 31.1 nejm knowledge+ gastroenterology
  32. 32.0 32.1 32.2 Rinella ME et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023 May; 77:1797. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36727674 https://journals.lww.com/hep/Fulltext/2023/05000/AASLD_Practice_Guidance_on_the_clinical_assessment.31.aspx
  33. 33.0 33.1 Lee CM et al. A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis. Am J Gastroenterol 2023 May; 118:840. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36305695 https://journals.lww.com/ajg/Abstract/2023/05000/A_Reappraisal_of_the_Diagnostic_Performance_of.20.aspx
  34. 34.0 34.1 Rinella ME, Lazarus JV, Ratziu V et al A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. June 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37364790 Free article. Review. https://journals.lww.com/hep/Fulltext/9900/A_multi_society_Delphi_consensus_statement_on_new.488.aspx
  35. 35.0 35.1 Yang, Y, Teng Y, Shi J et al Association of nonalcoholic fatty liver disease with colorectal adenomatous polyps and non-adenomatous polyps: a cross-sectional study. Eur J Gastroenterol Hepatol. 2023. Aug 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37642651
  36. 36.0 36.1 Liu C, Liu T, Zhang Q et al New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk. JAMA Netw Open. 2023;6(9):e2335511. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37747732 PMCID: PMC10520743 Free PMC article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809840
  37. 37.0 37.1 Qi X, Guo J, Fang C et al Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. Sci Rep. 2024 Jan 31;14(1):2592. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38296998 PMCID: PMC10831069 Free PMC article https://www.nature.com/articles/s41598-024-52482-w
  38. 38.0 38.1 Jang H et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med 2024 Feb 12; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/38345802 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2814646
  39. 39.0 39.1 Kim KS et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: Nationwide population based study. BMJ 2024 Feb 13; 384:e076388 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38350680 PMCID: PMC10862140 Free PMC article https://www.bmj.com/content/384/bmj-2023-076388

Patient information

steatosis (nonalcoholic fatty liver disease) patient information

Database